Global Calcium Channel Blocker Market Size study & Forecast, by Drug Class (Dihydropyridine, Benzothizepine, Phenylalkylamine), Distribution Channel (Hospitals, Retail Pharmacies, and Others) and Regional Analysis, 2022-2029

Global Calcium Channel Blocker Market Size study & Forecast, by Drug Class (Dihydropyridine, Benzothizepine, Phenylalkylamine), Distribution Channel (Hospitals, Retail Pharmacies, and Others) and Regional Analysis, 2022-2029

Global Calcium Channel Blocker Market is valued approximately USD XXX billion in 2021 and is anticipated to grow with a healthy growth rate of more than 5.1% over the forecast period 2022-2029. Calcium channel blockers are a class of drugs that lower blood pressure by stopping calcium from entering heart and artery cells. Stronger cardiac muscle contractions are caused by calcium. Calcium channel blockers facilitate this by allowing blood arteries to relax, which increases the flow of blood and ensures that the heart receives the necessary amount of oxygen. The market growth is driven by significant factors such as increase in cardiovascular diseases and rising demand for Oral Drugs.

Heart failure is a chronic, incapacitating cardio-renal-metabolic condition that affects at least 60 million people globally, according to a news release published by Boehringer Ingelheim GmbH in August 2021. There is an urgent need for novel treatment alternatives as heart failure prevalence rises. Additionally, the market is anticipated to rise due to rising hypertension rates, an increase in hospitals, and government efforts. For instance, the American Hospital Association estimates that there were 6,090 hospitals in the United States as of 2021. According to data updated by the World Health Organization (WHO) in August 2021, more than 700 million people worldwide have untreated hypertension, and as of that year, 1.28 billion people worldwide had hypertension, a sharp increase over the previous few decades. However, lack of skilled professionals’ stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Calcium Channel Blocker Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is expected to hold a major market share owing to increasing prevalence rate of cardiovascular diseases. However, Asia Pacific is expected to be the fastest growing region due to large number of generic manufacturer and developing healthcare facilities.

Major market player included in this report are:
Bausch Health Company Inc.
Abbvie Inc
Lupin Pharmaceuticals, Inc
Arbor Pharmaceuticals LLC
Alvogen
Exela Pharma Sciences, LLC
Covis Pharma BV
Novartis AG
GlaxoSmithKline LLC
Pfizer Inc


Recent Developments in the Market:

The FDA approved Norliqva (amlodipine) oral solution in February 2022 to treatment hypertension in adults and children aged 6 and older, as well as to prevent coronary artery disease.

The American Food and Drug Administration (FDA) received provisional permission in May 2022 for Zydus Worldwide DMCC's subsidiary to commercialize Selexipag tablets for the treatment of pulmonary arterial hypertension (PAH) in adults.
Global Calcium Channel Blocker Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage
Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered
Drug Class, Distribution Channel, Region
Regional Scope
North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope
Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below.
By Drug Class:
Dihydropyridine
Benzothizepine
Phenylalkylamine
By Distribution Channel:
Hospitals
Retail Pharmacies
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australi.
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Companies Mentioned

Bausch Health Company Inc.
Abbvie Inc
Lupin Pharmaceuticals, Inc
Arbor Pharmaceuticals LLC
Alvogen
Exela Pharma Sciences, LLC
Covis Pharma BV
Novartis AG
GlaxoSmithKline LLC
Pfizer Inc

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.